# A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

> **NCT02546323** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 543 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02546323
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-17
- **Primary completion:** 2019-01-29
- **Final completion:** 2019-01-29
- **Target enrollment:** 543 (ACTUAL)
- **Last updated:** 2019-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546323, "A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02546323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*